Sean J Whelan

US Patent:

8034355, Oct 11, 2011

Filed:

Oct 6, 2006

Appl. No.:

12/089353

Inventors:

Sean Whelan - Cambridge MA, US
Jianrong Li - Columbus OH, US

Assignee:

Presidents and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 39/205
A61K 39/12
C12N 7/04

US Classification:

4242241, 4241991, 435236

Abstract:

The invention relates to an attenuated non-segmented negative-sense RNA virus characterized by at least one mutation in the L gene wherein the mutation reduces viral replication, the methods of manufacturing and methods of use.

US Patent:

20120064111, Mar 15, 2012

Filed:

Jul 14, 2011

Appl. No.:

13/183232

Inventors:

Sean Whelan - Cambridge MA, US
Jianrong Li - Columbus OH, US

International Classification:

A61K 39/205
C12N 7/01
A61P 35/00

US Classification:

4241991, 4352351

Abstract:

The invention relates to an attenuated non-segmented negative-sense RNA virus characterized by at least one mutation in the L gene wherein the mutation reduces viral replication, the methods of manufacturing and methods of use.

US Patent:

20140018338, Jan 16, 2014

Filed:

Jan 24, 2012

Appl. No.:

13/979179

Inventors:

Kartik Chandran - Brooklyn NY, US
Sean Whelan - Cambridge MA, US
Thijn Brummelkamp - Amsterdam, NL
Jan Carette - Palo Alto CA, US
Matthijs Raaben - De Belt, NL

International Classification:

G01N 33/50
A61K 31/55
A61K 31/566
C12Q 1/70
G01N 33/569

US Classification:

514178, 514 44 A, 435 613, 435 11, 435 792, 435 5, 514217

Abstract:

Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus.